The purpose of this study is to report toxicity and outcome results in patients with gynaeco logical tumours treated with a final boost using extra-cranial stereotactic radiotherapy (SRT) with a linac-based micro-multileaf collimator technique as an alternative to high-dose rate brachytherapy (HDR-BT). Since January 2002, 26 patients with either endometrial (n = 17) or cervical (n = 9) cancer were treated according to this protocol: 45-50.4 Gy external radiother apy (RT) to the pelvic ± para-aortic regions followed by a final SRT boost of 2 x 7 Gy to the vaginal vault (4-7 day interval between fractions). Median age was 62 years (37-74 range).
Introduction
Radiotherapy (RT) is frequently used in the postoperative treatment of endometrial and cervical cancer patients. External whole-pelvic RT (WPRT) followed by intracavitary brachytherapy (BT) at either low-dose (1) or high-dose rate (HDR) (2, 3) to a boost volume including the vaginal vault is one of the recommended treatment approaches.
External beam stereotactic RT (SRT) may alternatively be used to treat the final boost volume with time-dose fractionation schedules similar to those with HDR-BT but with potential advantages such as a simplified radiation protection Technology in Cancer Research & Treatment, Volume 9, Number 5, October 2010 and a potential improvement in target dose distribution. This was first suggested by Low et al., back in 2002 when they published a study in which an applicator guided external beam IMRT technique was used as alternative to BT for the treatment of locally advanced gynecologic tumors (4).
We reported in 2005 on the feasibility and preliminary tolerance results of SRT in 16 gynecologic patients, on the reproducibility of target repositioning with an inflated rectal balloon, and on a comparative treatment planning exercise between SRT and HDR-BT showing the former to be an acceptable treatment alternative compared to the later (5). Here we present more mature results on the tolerance and outcome of 26 patients treated with adjuvant RT for cervical or endometrial cancers with a SRT boost to the vaginal vault. While SRT has already been reported as a salvage treatment technique for pelvic relapses from gynecologic tumors, this is the first study to report on patients treated with this technique for a pure adjuvant purpose (6, 7).
Materials and Methods

Patients
From January 2002 to August 2008, 26 consecutive women with either cervical cancer (9 patients) or endometrial cancer (17 patients) have been treated with a final SRT boost to the vaginal vault with a pure adjuvant purpose. Patient, tumor, and treatment characteristics are summarized in Tables 1  and II . Age ranged from 37 to 74 years (median, 62 years).
According to the FIGO classification (8) stage at diagnosis was: stage I, in 17; stage II, in 7; and stage III, in 2.
Treatment
All patients were treated first to clinical target volume 1 (CTV1: pelvic lymph nodes +/-para-aortic nodes + tumor bed) with a 4-field "box" technique in the supine position. All fields were treated daily, 5 days-a-week with 15-MV X-rays. The prescribed dose to the pelvis was 45 Gy (1.8 Gy/fraction) in 22. For the remaining 4 patients, all with para-aortic nodal involvement, a dose of 45 Gy and of 50.4 Gy was prescribed to the para-aortic and pelvic regions, respectively.
The treatment boost to clinical target volume 2 (CTV2: vaginal vault, defined as 3 cm of vagina from the vaginal apex) was delivered under stereotactic conditions with a commercially available micromultileaf collimator (mMLC) based linear accelerator. This treatment unit delivers 6 MV X-rays and is able to perform dynamic-arc treatments, as well as IMRT (Novalis, BrainLAB A:G., Heimstetten, Germany). Before delivering the boost dose to CTV2, patients were immobilized with a customized vacuum body cast and optimally repositioned with the help of an infrared (IR)-guided system developed for extracranial SRT (ExacTract, BrainLAB A:G., Heimstetten, Germany). This system has previously been described in detail by us and Soete et al., (5, 9) . Briefly, five to seven IR reflecting metallic markers are asymmetrically fixed treatment completion according to the RTOG/EORTC scoring system (11). Late toxicity was scored after a minimum 6 month follow-up period. Late bladder and lower GI toxicity were scored according to the RTOG/EORTC scoring system (11), while sexual late effects where scored according to the SOMA (symptoms, objective, management, analytic) scoring system (12) . Gynecological examination and abdomino-pelvic CTs were performed every 6 months after the first year of treatment completion to respectively assess for local disease control and to rule out any evidence of distant failure.
Statistical Analysis
The association of independent variables and response variables was compared using a non-parametric analysis. Fisher exact test for proportions categorical variables and the Wilcoxon Rank Sum test were used to compare medians of continuous variables. We used the Kaplan-Meier method to assess urinary and rectal late toxicity as well as diseasespecific survival and overall survival (13). Long-rank test and Cox regression analysis were performed to assess for the level of correlation between treatment-related factors and late toxicity either urinary or rectal. The statistical analysis was performed using STATA version 10.1 (StataCorp., College Station, TX, USA).
Results
The SRT boost was well tolerated without interruption. The incidence (crude rates) of acute and late reactions is presented in Table III . Only two patients presented with Grade 3 acute toxicity while on treatment, one urinary and one rectal, which regressed after treatment completion in both cases.
to the skin of the abdomen just before performing the planning CT. The position of the isocenter with regard to the IR markers is calculated by the planning system. Before each treatment session the markers are placed back on the patient. Their spatial arrangement is detected by a pair of IR cameras mounted to the treatment room's ceiling to reproduce the same coordinates when repositioning the patients for daily treatment.
To further limit target motion and to help to improve the target defining process in the simulation CT, a magnetic resonance (MR) endorectal probe was used for the CTV2 simulation and treatment. Sodium phosphate enemas were used to evacuate the rectum the night before and again one to two hours before each procedure. In order to reduce anxiety and prevent or alleviate potential painful rectal spasms during the simulation or treatment intervals, alprazolam of 0.5 mg per os was prescribed. After introducing the probe in the rectum, 60 mL of air were introduced with a syringe. The inflated probe was then gently pulled towards the anus. No special care was taken to reproduce bladder filling during treatment.
Patients were then fitted in their immobilization casts, skin metallic markers were fixed on their respective spots, and the IR guided set-up was undertaken.
Simulation CT images were taken in 3-mm increments over the region of interest. The CTV2 and organs at risk (OARs) (i.e., rectum, bladder, small bowel, and femoral heads) were contoured on sequential axial CT slices. The CTV2 was expanded uniformly by 6 to 10 mm in all directions except in the posterior direction (towards the rectal wall) where a reduced margin of 6 mm was employed to produce the planning target volume (PTV). All patients but one were treated with IMRT to CTV2; the remaining patient was treated with a dynamic-arc RT technique. Among patients treated with IMRT a single isocenter was used with 5-15 fields. In all cases a dose of 2 × 7 Gy to the PTV with 4 to 7 days interval between fractions was prescribed and delivered in accordance with recommendations for HDR-BT by Orton et al., and by the American Brachytherapy Society (2, 10).
Four patients, three with cervical squamous carcinoma (stage IIB-IIIB) and one with a clear cell endocervical adenocarcinoma (stage IB2G3), received concomitant cisplatin in addition to RT. Preoperative neoadjuvant chemotherapy was prescribed in two additional patients: carboplatin and paclitaxel in one patient with an endometrial and uterine tube adenocarcinoma, and adriamycin in one patient with a uterine sarcoma (stage IIBG2).
Toxicity Scoring and Outcome Assessment
Urinary and lower GI acute effects were scored every week during treatment and 5-6 weeks and again 3 months after surgery for endometrial or cervical tumors. Our preliminary results are very similar to published results with HDR-BT.
Target repositioning, based on previously reported virtual simulation and resimulation studies with CT-to-CT registration of either IR metallic markers or pelvic bone structures was satisfactory. An optimal target dose distribution was obtained with 10 mm margins around CTV2 (5). The use of a rectal balloon, in addition to the repositioning with IR metallic markers, aimed to reduce target motion and to exclude from the high dose region as much rectal volume as possible (5).
Late rectal complications after HDR-BT have been reported to range between 5-30% (14). Indeed, Chun et al., reported an 8% crude incidence of low-GI ≥ grade-2 late toxicity after a HDR-BT boost, similar to ours (i.e., 11.5%) (14). Moderate to severe late rectal toxicity has been reported to correlate with maximum dose to the rectal wall (15) . According to Cheng et al., proximal rectal dose assessment would be more influential on late rectal toxicity than rectal dose estimated according to International Commission of Radiation Units and Measurement Report 38 guidelines (16). They recommended a maximal proximal rectal dose <62 Gy (adding the dose to the rectum from WPRT and from HDR-BT) if an unacceptable risk of late rectal toxicity is to be avoided (15) . The maximum dose to the rectum was considered to match the prescribed dose to the CTV2 in our series. This is best illustrated in our previous report published in 2005 (figure 2, reference # 5) in which DVHs for the rectum were shown for 2 patients in a planning setting comparing SRT and HDR-BT. Thus, assuming that the prescribed dose to the CTV2 would have been the maximum dose received by the rectum the estimated maximum dose to the rectal wall in our series was 64.4 Gy (i.e., 50.4 Gy to CTV1 + 14 Gy to CTV2) for the three patients with ≥ grade-2 late low-GI toxicity, while it was 59 Gy (i.e., 45 Gy to CTV1 + 14 Gy to CTV2) for 22 out of the 23 patients with ≤ grade-1 late low-GI toxicity.
No patient developed Grade 3 acute sexual toxicity. Grade 1 acute sexual toxicity was observed in 6 patients (dyspauremia in 1, synechiae in 1, and dryness in 4), whereas Grade 2 was reported in 4 patients (pruritus in 1 and dryness in 3).
After a median follow-up of 47 months (4-77, range), only one patient presented with grade-2 late urinary toxicity at 66 months follow-up. Grade 2 or higher late low-GI toxicity was observed in three patients, all belonging to the group of four patients receiving 50.4 Gy WPRT (the highest doses to the pelvis). Furthermore, two of these three patients received concomitant cisplatin while on RT. The actuarial 3-year probability of ≥Grade-2 late urinary and low-GI toxicity-free survival were 100% and 84% ± 8,8 %, respectively ( Figures  1 and 2) .
Late sexual side effects were observed in 13 patients, 7 with grade-1 (vaginal dryness in 5 patients and pruritus in 2), 4 with grade-2 (synechiae in 3, and stenosis in 1) and 1 with grade-3 (dryness).
The overall 3-year actuarial failure-free survival rate was 96 % ± 3.9 % and the 3-year overall survival rate was 95 % ± 4.2 %. Two patients with cervical cancer (1 stage IIIB and 1 stage IIB) developed a central pelvic recurrence at 4 and 12 months after RT, respectively. Surgical salvage was undertaken with one patient dying 17 months later and one patient alive with disease 6 months after salvage surgery. One patient with cervical cancer stage IIB developed lung metastases 43 months after treatment and is presently alive with disease 4 months later.
Discussion
As suggested in this report, extracranial SRT can successfully deliver highly conformal irradition to the vaginal vault after December 2008, we switched to image guided radiotherapy techniques to treat similar patients using three fiducial markers implanted in the vaginal vault for an optimal treatment reproducibility and simultaneously stopping the use of the inflated endorectal probe to limit internal organ motion.
As shown in our previous report, in a comparative planning exercise implemented on two patients, the bladder dose distribution was more favorable with HDR-BT than with SRT (both optimized IMRT and dynamic arc comformation). Although, grade-2 late urinary toxicity was observed in only one patient in the present series a longer follow-up may be required to determine the clinical significance of the relatively higher bladder dose with SRT techniques compared to HDR-BT.
Mild to severe late vaginal reactions and late sexual dysfunction may be observed in 35% to 55% of HDR-BT patients (17). In our study late sexual toxicity was observed in 12 of 25 patients but only in 5 (20%) late sexual toxicity was ≥ grade-2. Sexual dysfunction was already present prior to radiotherapy for most patients probably related to anatomic/ physiologic and psychosocial reasons such as the presence of a shortened vagina following radical hysterectomy preventing from penetration. In addition, oestrogen deficiency after ovarian ablation may cause vaginal dryness. This status may be worsened by RT causing severe atrophy, fibrosis, and loss of lubrication.
In our previous report we showed, that compared to HDR-BT, dose homogeneity can potentially be improved with SRT (5). Indeed, when boosting the vaginal vault with BT the dose is usually prescribed at a depth of 0.5 cm. When an especially designed cylinder is used to boost the top of the vagina, the 90% isodose volume has an ovoidal shape that may not completely cover the non-ovoidal shape of the target. It is not unusual that the target extends outside the 90% isodose line, especially proximally in a cranio-caudal axis. This is an important issue, considering that local control after HDR-BT is related to the PTV-DVH and to the minimum dose to the target volume for cancer of the cervix (18, 19) . In our series, however, a 3-year local control rate of 96 % was observed (i.e., 100%, 86%, and 50% for patients with stage I, II and III, respectively) very similar to published local control rates after HDR-BT for patients with similar pathologies and disease stages (4, 20).
Although, reimbursement policies in Europe may widely differ between countries and health systems (i.e., public versus private sectors) and considering that a fee for a yet non-standard treatment technique such as SRT for boosting the vaginal vault may be somehow arbitrary, present private practice fees are relatively similar both in Barcelona and in Geneva for standard external beam pelvic RT followed by a boost either with SRT or with HDR-BT ranging between 11000 and 12000 Euros.
In summary, preliminary results on feasibility, tolerance, and outcome with SRT are encouraging and may justify its use as an alternative to HDR-BT for gynecologic tumors. Since
